Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The transparency commission: evaluation and re-evaluation].

J F Bergmann1

  • 1Service de Médecine, Hôpital Lariboisière, 2, rue Ambroise Paré, F75475 Paris. jf.bergmann@lrb.ap-hop-paris.fr

Presse Medicale (Paris, France : 1983)
|July 4, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Characteristics of patients admitted from emergency units in 18 internal medicine departments and organisation of these departments: A cross sectional study from SNFMI (SiFMI study group) in 2015].

La Revue de medecine interne·2020
Same author

Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Acute pain Factors predictive of post-operative pain and opioid requirement in multimodal analgesia following knee replacement.

European journal of pain (London, England)·2015
Same author

Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.

Journal of viral hepatitis·2013
Same author

[Do we need to be afraid of biosimilars?].

La Revue de medecine interne·2011
Same author

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.

Alimentary pharmacology & therapeutics·2011
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

The French Transparency Commission offers scientific advice on drug utility and effective use. Their assessments influence drug reimbursement and pricing, promoting appropriate medication practices.

Area of Science:

  • Pharmacoeconomics
  • Health Technology Assessment
  • Drug Evaluation

Context:

  • Operates at the intersection of French/European drug marketing approval and national health/economic requirements.
  • Integral to the French pharmaceutical regulatory landscape.
  • Bridges scientific drug assessment with healthcare system needs.

Purpose:

  • To provide expert scientific advice on the utility, interest, and appropriate use of pharmaceutical products.
  • To evaluate new drugs and assess improvements in medical services offered by them.

Summary:

  • The Commission's opinion evaluates the medical service a new drug provides and its subsequent improvement.
  • This assessment is crucial for determining social security reimbursement rates.
  • It also informs the selling price set by regulatory administration.

Related Experiment Videos

Impact:

  • Facilitates informed decision-making in drug pricing and reimbursement.
  • Contributes to the optimal and cost-effective use of medications within the French healthcare system.
  • Enhances the value assessment of new drugs for healthcare providers and patients.